Related Experiment Video
Updated: Sep 17, 2026

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
Published on: May 22, 2026
The incidence of cancer among participants in controlled, randomized isoniazid preventive therapy trial
Abstract:
Cancer morbidity and mortality were examined among 11,894 Puerto Rican participants in a US Public Health Service preventive therapy trial begun in 1957. The mean duration of follow-up was 18 years (range 16-19 years). No statistically significant difference in overall cancer rates was observed between the participants in the trial assigned isoniazid and those assigned placebo. There were also no significant differences between the groups when rates for specific types of cancer and age-specific cancer rates were compared. No trend toward an increasing cancer rate in the isoniazid group was observed with the passage of time. The mortality rate due to cancer was similar in the two groups. These data coupled with other information reported in the literature provide substantial evidence that isoniazid, when given in the usual therapeutic doses, is not carcinogenic in humans.
Related Concept Videos
Cancer Prevention
Some...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Mutagenicity and Carcinogenicity
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Hazard Ratio
For example, in a clinical trial evaluating a...